Clinical Trials
- DevRobust Treatment for Mal de Débarquement Syndrome
- Transcranial Electrical Stimulation for Mal de Debarquement Syndrome
- Transcranial Magnetic Stimulation for Mal de Debarquement Syndrome
- Treatments of Mal de Debarquement Syndrome (MdDS) by Habituation of Velocity Storage
- WAVES for Mal de Debarquement Syndrome
- A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas
- A Study of LY3435151 in Participants With Solid Tumors
- A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg
- ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
- Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma
- Focused Ultrasound to Promote Immune Responses for Undifferentiated Pleomorphic Sarcoma
- Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery
- Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study
- Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma
- Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas
- Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery
- A Case Control Study of Patients With Diagnosis of Malignant Hyperthermia
- Effectiveness of Carbon Filters to Reduce the Anesthetic Gas Concentration in an Anesthetized Patient
- Gene Mutation Spectrum of Malignant Hyperthermia in China
- Malignant Hyperthermia in Czech Republic: Description of the Biggest Slavonic Group of Patients Investigated for Risk of Malignant Hyperthermia
- Malignant Hyperthermia Registry and Genetic Testing
- Multisystem Features of Malignant Hyperthermia or Rhabdomyolysis Related to RYR1 Variants
- Screening of Malignant Hyperthermia Susceptible Individuals
- Spanish Registry of RYR1 and CACNA1S Polymorphisms
- 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours
- 18F-FSPG PET/CT for Cancer Patients on Therapy
- A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma
- A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma
- A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPM
- A Phase 1 Dose Escalation Study of VS-5584 Administered in Combination With VS-6063, in Subjects With Relapsed Malignant Mesothelioma
- A Phase 1 Study of PRT3645 in Participants With Select Advanced or Metastatic Solid Tumors
- A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
- A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma
- A Phase I/II Study of First Line Vorinostat With Pemetrexed-cisplatin, in Patients With Malignant Pleural Mesothelioma
- A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line Chemotherapy
- A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma
- A Phase II Study of Single-agent DOVitinib in Advanced Malignant PlEural Mesothelioma Which Has Progressed Following Prior Platinum-Antifolate Chemotherapy
- A Phase II Study of the Association of Glivec® Plus Gemzar® in Patients With Unresectable, Refractory, Malignant Mesothelioma
- A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma
- A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma
- A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic Mesothelioma
- A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers
- A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma
- A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma
- A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma
- A Study of Immunotherapy Drugs Nivolumab and Ipilimumab in Patients w/Resectable Malignant Peritoneal Mesothelioma
- A Study of LY3023414 in Participants With Advanced Cancer
- A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer
- A Study of Nivolumab and Chemotherapy Followed by Surgery for Mesothelioma
- A Study of Pembrolizumab and Radiation Therapy in People With Mesothelioma
- A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)
- A Study of SGN-BB228 in Advanced Melanoma and Other Solid Tumors
- A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
- A Study of VEGF-Antisense Oligonucleotide in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma
- A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients
- Accelerated Hypofractionated Radiotherapy in the Treatment of Malignant Pleural Mesothelioma
- Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma
- ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.
- Alvopem® (Pemetrexed) Safety Assessment
- Amatuximab for High Mesothelin Cancers
- AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma
- AMT-151 in Patients With Selected Advanced Solid Tumours
- An Efficacy and Safety Study With Vandetanib to Treat Inoperable or Relapsed Malignant Mesothelioma
- An Efficacy Study of Milataxel (TL139) Administered Orally for Malignant Mesothelioma
- An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma
- An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma
- Anti-Mesothelin Immunotoxin LMB-100 Followed by Pembrolizumab in Malignant Mesothelioma
- Antineoplaston Therapy in Treating Patients With Advanced Mesothelioma
- APG-2449 in Patients With Advanced Solid Tumors
- ATREUS – Phase II Study on the Activity of Trabectedin in Patients With Malignant Pleural Mesothelioma (MPM)
- Autologous Redirected RNA Meso-CIR T Cells
- Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma
- Biomarkers of Angiogenesis and Disease in Patients With Unresectable Malignant Mesothelioma Treated on Clinical Trial CALGB-30107
- Biomarkers to Detect Mesothelioma Early in Patients Exposed to Asbestos or Vermiculite
- Bortezomib in Treating Patients With Malignant Pleural Mesothelioma
- Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors
- Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery
- Capecitabine in Treating Patients With Malignant Mesothelioma
- CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
- Carboplatin, Bevacizumab and Pemetrexed in the First-Line Treatment of Patients With Malignant Pleural Mesothelioma (MPM)
- Cardiac MRI Biomarker Testing (GCC 1618)
- Cediranib Maleate in Treating Patients With Malignant Mesothelioma That Cannot Be Removed By Surgery
- CheckpOiNt Blockade For Inhibition of Relapsed Mesothelioma
- Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural Mesothelioma
- Cisplatin With Alimta or Gemcitabine in Long Infusion for Mesothelioma
- Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery
- Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura
- Cisplatin, Interferon Alfa, Surgery, and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma
- Cisplatin, Pemetrexed and Bevacizumab for Untreated Malignant Mesothelioma
- Cisplatin, Pemetrexed, and Imatinib Mesylate in Malignant Mesothelioma
- Clinical Study of YS110 in Patients With Malignant Pleural Mesothelioma
- Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy
- Combination Chemotherapy Before Surgery in Treating Patients With Mesothelioma of the Lung
- Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Malignant Mesothelioma
- Combination Chemotherapy With or Without Surgery and Chemoradiotherapy in Treating Patients With Malignant Pleural Mesothelioma
- Combination Chemotherapy With or Without Surgery and Radiation Therapy in Treating Patients With Mesothelioma That Can Be Removed By Surgery
- Combination Gene Transfer and Chemotherapy
- Comparison of Progel Sealant to Standard of Care (SOC) for Patients Undergoing Decortication
- Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma
- Cryoablation for the Promotion of Local Tumor Infiltration in Patients With Mesothelioma
- CryoSpray Ablation(tm)in Malignant Airway Disease to Determine Safety, and Tissue Effect in the Lung (ICE the MAD)
- Cryotherapy in Treating Patients With Lung Cancer That Has Spread to the Other Lung or Parts of the Body
- Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
- Dasatinib in Resectable Malignant Pleural Mesothelioma
- Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma
- Decitabine in Treating Patients With Unresectable Lung or Esophageal Cancer or Malignant Mesothelioma of the Pleura
- DENdritic Cell Immunotherapy for Mesothelioma
- Dendritic Cell-based Immunotherapy Combined With Low-dose Cyclophosphamide in Patients With Malignant Mesothelioma
- Dendritic Cell-based Immunotherapy in Mesothelioma
- Dendritic Cells Loaded With Allogeneous Cell Lysate in Mesothelioma Patients
- Depsipeptide/Flavopiridol Infusion for Cancers of the Lungs, Esophagus, Pleura, Thymus or Mediastinum
- Direct Injection of Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma
- Do Your Genes Put You at a Higher Risk of Developing Mesothelioma
- Dose Individualization of Pemetrexed – IMPROVE-I
- Dose Individualization of Pemetrexed – IMPROVE-II
- Dose Individualization of Pemetrexed – IMPROVE-III
- DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
- Early Detection of Lung Cancer and Mesothelioma in Workers Exposed to Asbestos
- Early Diagnosis of Lung Cancer and Mesothelioma in Prior Asbestos Workers
- Early Palliative Care in Advanced Lung and Gastrointestinal Malignancies
- Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
- Ecteinascidin 743 in Treating Patients With Malignant Mesothelioma
- EF5 in Detecting Oxygen Level and Blood Vessels in Tumor Cells of Patients Undergoing Photodynamic Therapy for Intraperitoneal or Pleural Cancer
- Effect of Expression of CD74 and VEGF on Outcome of Treatment in Patients With Malignant Pleural Mesothelioma
- Effect of FAS and FAS Ligand Polymorphisms on Patients With Platinum-Based -Treated Malignant Pleural Mesothelioma
- Effect of HITHOC After Pleurectomy Decortication for Treatment of Malignant Pleural Mesothelioma
- Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma
- Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma
- Erlotinib Hydrochloride in Treating Patients With Malignant Peritoneal Mesothelioma
- Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung
- Evaluation of Cell Changes in Blood and Tissue in Cancers of the Lung, Esophagus and Lung Lining
- Evaluation of CRS-207 With Pembrolizumab in Previously Treated Malignant Pleural Mesothelioma (MPM)
- Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by Immunotherapy
- Extrapleural Pneumonectomy /Pleurectomy Decortication, IHOC Cisplatin and Gemcitabine With Amifostine and Sodium Thiosulfate Cytoprotection for Resectable Malignant Pleural Mesothelioma
- Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate
- Feasibility of an Early Palliative Care Intervention for Metastatic Cancer Patients. A Phase 2 Study.
- First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
- First-in-human Study of S-588210 (S-488210+S-488211)
- Four Versus Six Cycles of Pemetrexed/Platinum for MPM
- Ganetespib With Platinum, in Patients With Malignant Pleural Mesothelioma
- Gefitinib in Treating Patients With Malignant Mesothelioma
- Gemcitabine and Epirubicin in Treating Patients With Malignant Mesothelioma
- Gemcitabine in Long Infusion and Cisplatin for Malignant Pleural Mesothelioma Treatment
- Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for the Treatment of Resectable, Refractory, or Recurrent Abdominal or Pelvic Tumors in Pediatric Patients, T.O.A.S.T. I.T. Study
- Hemithoracic Irradiation With Proton Therapy in Malignant Pleural Mesothelioma
- High Resolution Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome
- High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or Mesothelioma
- Influence of Psychosocial Distress and Lifetime Trauma Exposure on Traumatic Stress Among Oncology Patients on Clinical Trials
- Inhaled Doxorubicin in Treating Patients With Advanced Solid Tumors Affecting the Lungs
- Intracavitary Cisplatin-Fibrin Localized Chemotherapy After P/D or EPP for Malignant Pleural Mesothelioma
- Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.
- Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion
- Intrapleural Cryotherapy for Malignant Pleural Mesothelioma
- Intrapleural Gene Transfer for Pleural Mesothelioma
- Intrapleural Measles Virus Therapy in Patients With Malignant Pleural Mesothelioma
- Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma
- Intravenous Magnesium in Patients Receiving Cisplatin
- IP3R Modulation by Cancer Genes in Mesothelioma
- Ipilimumab and Nivolumab in the Treatment of Malignant Pleural Mesothelioma
- Isolated Thoracic Perfusion (ITP-F) for MPM
- Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery
- Liposomal-Cisplatin Analogue (L-NDDP) in Treating Patients With Malignant Pleural Mesothelioma
- Long Term Follow-up of Mesothelioma Patients and Their Family Members With Germline Mutations in BAP1 and Other Genes
- Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.
- MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI
- Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma
- Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
- MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma
- MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC
- Mesothelin and Osteopontin as Diagnostic Markers in Patients With Mesothelioma or Atypical Mesothelial Hyperplasia
- Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma
- Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma
- Mesothelin-Targeted Immunotoxin LMB-100 in People With Malignant Mesothelioma
- Mesothelioma and Radical Surgery 2
- Mesothelioma Avastin Plus Pemetrexed-cisplatin Study
- MesoTRAP: A Study Comparing Video-assisted Thoracoscopic Partial Pleurectomy/Decortication With Indwelling Pleural Catheter in Patients With Trapped Lung Due to Malignant Pleural Mesothelioma.
- Metronomic Chemotherapy Based on Adaptative Bio-mathematical Model of Oral Vinorelbine in Patients With NSCLC or MPM
- Mithramycin for Lung, Esophagus, and Other Chest Cancers
- Molecular Analysis of Thoracic Malignancies
- Molecular Predictors of Pemetrexed and Carboplatin Response in Malignant Pleural Mesothelioma (MPM) Patients
- MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma
- Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors
- Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
- Neoadjuvant Toripalimab Combined With Chemotherapy in the Treatment of Malignant Pleural Mesothelioma
- NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed
- Nintedanib (BIBF 1120) in Mesothelioma
- Nintedanib as Switch Maintenance Treatment of Pleural Malignant Mesothelioma
- Nintedanib in Treating Patients With Malignant Pleural Mesothelioma That Is Recurrent
- Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant Mesothelioma
- Nivolumab in Patients With Recurrent Malignant Mesothelioma
- Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) Patients
- Observational Prospective Analysis of Biological Characteristics of Mesothelioma Patients
- Observational Study in Patients With Previously Unresectable Malignant Pleural Mesothelioma Treated With Nivolumab and Ipilimumab (MESO-IMMUNE)
- Olaparib in Patients With HRD Malignant Mesothelioma
- Olaparib in People With Malignant Mesothelioma
- ONCONASE Plus Doxorubicin Versus Doxorubicin Alone For Patients With Malignant Pleural or Peritoneal Mesothelioma Who Have Had No More Than One Prior Chemotherapy Regimen
- Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma
- OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition
- Palliative Therapy With or Without Chemotherapy in Treating Patients With Malignant Mesothelioma
- Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma
- Pazopanib in Treating Patients With Malignant Pleural Mesothelioma
- Pembrolizumab + Defactinib In Pleural Mesothelioma
- Pembrolizumab and Hypofractionated Stereotactic Radiotherapy in Patients With Malignant Pleural Mesothelioma
- Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma
- Pemetrexed (ALIMTA) Plus Cisplatin Followed by Surgery and Radiation Therapy for Mesothelioma
- Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma
- Pemetrexed Disodium and Cisplatin Followed by Surgery With or Without Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma
- Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
- Pemetrexed Disodium/Observation in Treating Patients W/ Malignant Pleural Mesothelioma w/Out Progressive Disease After 1st Line Chemotherapy
- Pemetrexed Plus Gemcitabine as Front-Line Chemotherapy for Patients With Malignant Pleural or Peritoneal Mesothelioma
- Pemetrexed Plus Gemcitabine or Carboplatin for Patients With Advanced Malignant Pleural Mesothelioma
- Pemetrexed, Cisplatin, and Vitamin B12 in Treating Patients With Mesothelioma of the Chest That Cannot Be Removed by Surgery
- Pevonedistat Alone and in Combination With Chemotherapy in Patients With Mesothelioma
- PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
- Ph 2/3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin
- Pharmacogenetics Of Vinorelbine In Malignant Pleural Mesothelioma Patients
- Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma
- Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
- Phase 1/2 Trial of TC-210 T Cells in Patients With Advanced Mesothelin-Expressing Cancer
- Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide
- Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin
- Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)
- Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma
- Phase II Study of Bevacizumab, Pemetrexed and Carboplatin as First-Line Therapy in Malignant Pleural Mesothelioma
- Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM
- Phase II Study of Six Hours Low Dose Gemcitabine Plus Cisplatin in the Treatment for Advanced Pleural Mesothelioma
- Phase II Study of Valproate and Doxorubicin in Malignant Mesothelioma
- Phase II Trial of Alisertib (MLN8237) in Salvage Malignant Mesothelioma
- Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma
- Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas
- Pilot Study of Bisphosphonate Therapy (Zoledronic Acid) in Patients With Malignant Mesothelioma (UAB 0901)
- PIT: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma
- Placebo Controlled Study of VS-6063 in Subjects With Malignant Pleural Mesothelioma
- Pleurectomy/ Decortication (P/D) Preceded or Followed by Chemotherapy in Patients With Early Stage MPM
- Pleurectomy/Decortication (Neo) Adjuvant Chemotherapy and Intensity Modulated Radiation Therapy to the Pleura in Patients With Locally Advanced Malignant Pleural Mesothelioma
- Pleurectomy/Decortication Followed by Intrathoracic/Intraperitoneal Heated Cisplatin for Malignant Pleural Mesothelioma
- Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate
- Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma
- Printed Education Materials in Patients Who Are Finishing Treatment for Stage I, Stage II, or Stage IIIA Breast Cancer, Colorectal Cancer, Prostate Cancer, or Chest Cancer
- PRO1184 for Advanced Solid Tumors
- Prospectively Collected Pleural Biopsies for Validation of Malignant Pleural Mesothelioma Prognostic Biomarkers
- Psychosocial Needs and Exploration of Online Support for Patients With Mesothelioma
- PTK787/ZK 222584 in Treating Patients With Unresectable Malignant Mesothelioma
- Pulmonary Interstitial Lymphography in Early Stage Lung Cancer
- PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By Surgery
- Radiation Therapy in Preventing Metastatic Cancer in Patients Who Have Diagnostic Procedures to Identify Malignant Mesothelioma
- Radical Pleurectomy/Decortication (PD) and Intensity Modulated Radiotherapy (IMRT)
- Radiofrequency Ablation in Treating Patients With Refractory or Advanced Lung Cancer
- Raltitrexed in Treating Patients With Malignant Mesothelioma That Cannot Be Surgically Removed
- Rapid Autopsy and Procurement of Cancer Tissue
- Re-directed T Cells for the Treatment (FAP)-Positive Malignant Pleural Mesothelioma
- Real World Study of MPM in China
- Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers
- Rehabilitation by Effort for Patients With Advanced Bronchial Cancer
- Response Evaluation in Malignant Pleural Mesothelioma
- Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity
- S0509 – AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery
- S0722: Everolimus in Treating Patients With Pleural Malignant Mesothelioma That Cannot Be Removed By Surgery
- S9810: Gemcitabine Plus Cisplatin in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot Be Removed by Surgery
- Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma
- Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment
- Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)
- Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma
- SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II
- Screening of Alberta Asbestos Exposed Workers for Lung Cancer and Mesothelioma
- Serum Biomarkers in Diagnosis of Mesothelioma
- Short Neoadjuvant Hemithoracic IMRT for MPM
- Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
- Sorafenib in Previously Treated Malignant Mesothelioma
- Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.
- Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors
- SPECTAlung: Screening Patients With Thoracic Tumors for Efficient Clinical Trial Access
- Staging Procedures to Diagnose Malignant Pleural Mesothelioma
- Standard Chemotherapy With of Without Axitinib in Malignant Mesothelioma
- Stereotactic Magnetic Resonance Guided Radiation Therapy
- Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma
- Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)
- Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies
- Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for Malignant Pleural Mesotheliomas
- Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)
- Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
- Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
- Study of NGM831 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
- Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma
- Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
- Study of Pemetrexed in Mesothelioma and Lung Cancer Patients With Fluid Around the Lungs or Abdomen
- Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma
- Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours
- Study of RSO-021 in Patients With Malignant Pleural Effusion Due to Advanced/Metastatic Solid Tumors Including Mesothelioma
- Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment
- Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors
- Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin
- Study of the EZH2 Inhibitor Tazemetostat in Malignant Mesothelioma
- Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
- SU5416 in Treating Patients With Malignant Mesothelioma
- Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma
- Surgery and Photodynamic Therapy in Treating Patients With Malignant Mesothelioma
- Surgery for Mesothelioma After Radiation Therapy “SMART” for Resectable Malignant Pleural Mesothelioma
- Surgery Plus Intraoperative Peritoneal Hyperthermic Chemotherapy (IPHC) to Treat Peritoneal Carcinomatosis
- Surgery, Chemotherapy, and Radiation Therapy in Treating Patients With Peritoneal Cancer
- Switch-Maintenance Gemcitabine After First-Line Chemotherapy In Patients With Malignant Pleural Mesothelioma
- Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
- The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma
- The IMmunotherapy Pleural 5-ALA PDT
- Thromboelastography During Surgery for Malignant Pleural Mesothelioma
- Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
- Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma
- Tomotherapy Treatment for Mesothelioma
- Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma
- Transitions Project
- Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy
- Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso
- Trimodality Therapy for Malignant Pleural Mesothelioma
- Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural Mesotheliomas
- UNITO-001-A Phase II Study Niraparib Plus Dostarlimab in HRR/PDL1 Positive MPM/NSCLC
- uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the Lung
- Vaccine Therapy and Ganciclovir in Treating Patients With Mesothelioma
- Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or Mesothelioma
- Vaccine Therapy in Treating Patients With Stage I, Stage II, or Stage IIIA Non-small Cell Lung Cancer or With Stage I or Stage II Mesothelioma
- Vascularity Impact on the Treatment Outcome in Malignant Pleural Mesothelioma(VITMPM)
- Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma
- Video-Assisted Surgery or Talc Pleurodesis in Treating Patients With Malignant Mesothelioma
- Vinorelbine in Mesothelioma
- Window of Opportunity Study of VS-6063 (Defactinib) in Surgical Resectable Malignant Pleural Mesothelioma Participants
- αDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies
- αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors
- A Randomized, Open-label, LOSARTAN Therapy on the Progression of Aortic Root Dilation in Patients With Marfan Syndrome
- Analysis of Muscular Properties in Patients With MFS and EDS
- Angiotensin Converting Enzyme Inhibitors in Marfan Syndrome
- Atenolol Versus Losartan in the Prevention of Progressive Dilation of the Aorta in Marfan Syndrome
- Biological Collection for Marfan and Related Syndromes
- Cardiorespiratory and Muscular Rehabilitation of Children and Young Adults With Marfan Syndrome.
- Children and Adolescents With Marfan Syndrome: 10,000 Healthy Steps and Beyond
- Circulating Transforming Growth Factor Beta (TGF-β) in Individuals With Marfan Syndrome
- Classifying Ectopia Lentis in Marfan Syndrome Into Five Grades of Increasing Severity
- Clinical Variability in Marfan Syndrome
- Comparison of Aliskiren vs Negative Controls on Aortic Stiffness in Patients With MFS
- Comparison of Medical Therapies in Marfan Syndrome.
- Comparison of Two Medications Aimed at Slowing Aortic Root Enlargement in Individuals With Marfan Syndrome–Pediatric Heart Network
- Complex Aortic Aneurysm Repair Using Physician Modified Endografts and Custom Made Devices
- Development of a Blood Test for Marfan Syndrome
- Effect on the Quality of Life of a Therapeutic Education Program in Patients With Marfan Syndrome
- Effects of Losartan Versus Atenolol on Aortic and Cardiac Muscle Stiffness in Adults With Marfan Syndrome
- Effects of Personalized Training at Home Combining Endurance and Resistance in Patients Suffering From Marfan Syndrome
- Generation of Marfan Syndrome and Fontan Cardiovascular Models Using Patient-specific Induced Pluripotent Stem Cells
- Living With Marfan Syndrome and Your Aorta
- Living With Marfans and Your Aorta: Surgical Outcomes Study
- Losartan Versus Atenolol for the Treatment of Marfan Syndrome
- Marfan Syndrome (MFS) and Facial Dysmorphism: Non-invasive 3D Assessment
- Marfan Syndrome Moderate Exercise Pilot
- Measurement of Heart-carotid Pulse Wave Velocity (hcPWV) by Laser Doppler Vibrometry (LDV)
- Mortality and Morbidity Outcomes in Marfans
- Nebivolol Versus Losartan Versus Nebivolol+Losartan Against Aortic Root Dilation in Genotyped Marfan Patients
- Proximal Aortopathy in Scotland – Epidemiology and Surgical Outcomes
- Psychological Support in Adult Patients With Marfan Syndrome
- Randomized, Double-blind Study for the Evaluation of the Effect of Losartan Versus Placebo on Aortic Root Dilatation in Patients With Marfan Syndrome Under Treatment With Beta-blockers
- Safety and Performance of POLYTHESE® Vascular Prosthesis
- Studies of Heritable Disorders of Connective Tissue
- Study of Heritable Connective Tissue Disorders
- Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan Syndrome
- Surgical Treatment of Marfan Syndrome With Subluxation Lens
- Tele-Clinic Visits in Pediatric Marfan Patients Using Parental Echo: The Future?
- The Oxford Marfan Trial
- Thoracic Aortic Dilatation Syndromes
- Transcriptomic Study of Adult Population With Marfan Syndrome
- Application of UCPCR as a Testing Tool for Identification of MODY Patients in the UAE
- Contribution of Hyperinsulinemia vs. Hyperglycemia to Insulin Resistance in Type 1 Diabetes and Maturity Onset Diabetes of the Young, Type 2 (MODY2)
- Genetic Causes of Gestational Diabetes in the Emirati Population
- Identifying Maturity-onset Diabetes of the Young in Emirati Patients
- Impact of SGLT2 on Glucosuria in HNF1A-MODY
- Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes
- MODY in Young-onset Diabetes in Different Ethnicities
- Pathophysiological Implications of the Incretin Hormones in Maturity Onset of Diabetes of the Young (MODY)
- Switching From Insulin to Sulfonylurea in Diabetes Associated With Variants in MODY Genes
- The Effect of GIP and GLP-1 on Insulin and Glucagon Secretion in Patients With HNF1A-diabetes Treated With or Without Sulphonylurea
- The Effects of GLP-1 in Maturity-Onset Diabetes of The Young (MODY)
- Comparison Of Surfactant Lung Lavage With Standard Care In The Treatment Of Meconium Aspiration Syndrome
- Effect Of Intrapartum Oropharyngeal (IP-OP) Suction on Meconium Aspiration Syndrome
- Helium Oxygen Mixture in the Treatment of Meconium Aspiration Syndrome
- High Flow Ventilation With Volume Guarantee
- Lung Lavage With Dilute Poractant Alfa for Meconium Aspiration Syndrome
- Maternal Hyperoxygenation for Intrapartum Fetal Heart Rate Tracing Abnormalities
- Meconium Aspiration and Tracheal Suctioning—Feasibility Study
- Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome
- Pulmonary Function Using Non-invasive Forced Oscillometry
- Role of Endotracheal Suction on the Occurrence of Meconium Aspiration Syndrome in Non-vigorous Meconium Stained Babies
- Surfactant Lavage vs. Bolus Surfactant in Neonates With Meconium Aspiration
- Time of Positive Pressure Ventilation in Non-vigorous Infants Born Through Meconium-stained Amniotic Fluid
- Use of Heliox in the Management of Neonates With Meconium Aspiration Syndrome
- 131I-Omburtamab, in Recurrent Medulloblastoma and Ependymoma
- A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
- A Pediatric Phase I Trial of RMP-7 and Carboplatin in Brain Tumors
- A Phase 1 Study of ZSP1602 in Participants With Advanced Solid Tumors
- A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
- A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors
- A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)
- A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma
- A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors
- AflacST1901: Peds WP1066
- An East Asian Study of LDE225
- Apatinib Combined With Temozolomide and Etoposide Capsules in the Treatment of Recurrent Medulloblastoma in Children
- Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET
- Child’s Study of the Impact of PF Lesion on Motor Skills, Language, Cognitive Functioning and Social Cognition
- Children’s and Adolescents’ Medulloblastoma Molecular Subgroups in China
- Clinical Trial to Assess the Safety and Efficacy of AloCELYVIR With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) in Combination With Radiotherapy or Medulloblastoma in Monotherapy
- Combination of Irinotecan and Temozolomide in Children With Brain Tumors.
- Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors
- Dosimetry Guided PRRT With 90Y-DOTATOC
- Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
- Dual Task Training On Children With Ataxia After Medulloblastoma Resection
- Effect of Metformin on Behaviour and the Brain in Children Treated for a Brain Tumour
- Efficacy of Dual Task Training on Children With Ataxia After Medulloblastoma Resection
- Eflornithine (DFMO) for Medulloblastoma
- Establishment and Clinical Application of Risk Classification Model Based on Molecular Typing of Medulloblastoma in Children
- Evaluation of LY2606368 Therapy in Combination With Cyclophosphamide or Gemcitabine for Children and Adolescents With Refractory or Recurrent Group 3/Group 4 or SHH Medulloblastoma Brain Tumors
- Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors
- Fimepinostat in Treating Brain Tumors in Children and Young Adults
- GD2-CAR T Cells for Pediatric Brain Tumours
- GDC-0449 in Treating Young Patients With Medulloblastoma That is Recurrent or Did Not Respond to Previous Treatment
- HeadStart4: Newly Diagnosed Children (
- High Risk Primitive Neuroectodermal (PNET) Brain Tumors in Childhood
- Hyperfractionated Versus Conventionally Fractionated Radiotherapy in Standard Risk Medulloblastoma
- Immuno 1: Immune Reconstitution Following Conventional or High-Dose Chemotherapy With Stem Cell Transplant
- Impact of Ga-68 DOTATOC PET-CT Imaging in Management of Neuroendocrine Tumors
- Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma
- Infusion of Panobinostat (MTX110) Into the Fourth Ventricle in Children and Adults With Recurrent Medulloblastoma
- Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors or Meningiomas Expressing SST2A
- Metronomic and Targeted Anti-angiogenesis Therapy for Children With Recurrent/Progressive Medulloblastoma
- Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma
- Molecular-Guided Therapy for Relapsed and Refractory Childhood Cancer
- Multicenter Pilot-study for the Therapy of Medulloblastoma of Adults
- Multicenter Register for Children and Young Adults With Intracranial Localized Medulloblastoma, CNS-PNET or Ependymoma
- NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors
- NKG2D-based CAR T-cells Immunotherapy for Patient With r/r NKG2DL+ Solid Tumors
- Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG
- Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
- Phase I Study of APX005M in Pediatric CNS Tumors
- Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs
- Physical Activity on Postural Stability and Coordination in Children With Posterior Fossa Tumor
- Quantitative Assessment of Radiation-induced Neuroinflammation – A Proof of Principle Study
- Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma
- Safety and Efficacy Study of TPI-287 in Neuroblastoma and Medulloblastoma
- Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors
- Social Cognition and Brain Integrity in Survivors of Pediatric Medulloblastoma
- Study Assessing the Feasibility of a Surgery and Chemotherapy-Only in Children With Wnt Positive Medulloblastoma
- Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma
- Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors
- Study of Tomotherapy HD in Medulloblastoma
- Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery
- Theranostics: 68GaDOTATOC and 90YDOTATOC
- Therapy Optimization Trial for the Treatment of Relapsed or Refractory Brain Tumors in Children
- TPI 287 in Patients With Refractory or Recurrent Neuroblastoma or Medulloblastoma
- Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor
- Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor
- Valproic Acid in Childhood Progressive Brain Tumors
- Vismodegib in Treating Patients With Recurrent or Refractory Medulloblastoma
- Vismodegib in Treating Younger Patients With Recurrent or Refractory Medulloblastoma
- Volitinib in Treating Participants With Recurrent or Refractory Primary CNS Tumors